Advertisement

Topics

Alphamab/3D Medicines PD-L1 Antibody Approved for US Trial

01:17 EST 2 Dec 2016 | ChinaBio Today

Suzhou Alphamab and 3D Medicines (Sichuan) have received approval from the US FDA to begin clinical trials of KN035, a PD-L1 bi-specific immunotherapy. The two companies partnered on the molecule earlier this year: Alphamab discovered and developed the product, while 3D will be in charge of the clinical trials and commercialization. KN035 is a fusion protein of a PD-L1 single domain antibody and Fc. More details....

Share this with colleagues:  

Original Article: Alphamab/3D Medicines PD-L1 Antibody Approved for US Trial

NEXT ARTICLE

More From BioPortfolio on "Alphamab/3D Medicines PD-L1 Antibody Approved for US Trial"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...